ClinicalTrials.gg
CompletedNCT00069121Updated Mar 6, 2020Results posted

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

A Phase 3 interventional study of Capecitabine and Oxaliplatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 232 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2003, registered Sep 2003).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,886
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.

Enrollment
8th of 173
1,886 · median 55
Started
2003
with 12 others
Phase 3
32 of 179
4 open now
Registered
9th of 179
by date
Lead sponsor
16 of 179
Hoffmann-La Roche

Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 8th largest by enrollment of the 173 interventional ones that give a count, is one of 13 that started in 2003, is one of 32 in phase 3, and was the 9th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies testing capecitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery for colon cancer and no previous chemotherapy. Patients will be randomized to receive either 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment is until disease progression and the target sample size is 500+ individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed colon carcinoma, AJCC/UICC Stage III (Dukes stage C)
  • Complete tumor resection; Patients operated with curative intent and with no macroscopic or microscopic evidence for remaining tumor who can be randomized to either treatment arm within 8 weeks after surgery. As this is an adjuvant trial patients should never have had any evidence of disease (including presence of tumor cells in the ascites).
  • Have a of at least 5 years

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Sexually active males and females (of ) unwilling to practice during the study
  • Previous cytotoxic chemotherapy, radiotherapy or immunotherapy, for the currently treated colon cancer
  • Patients who have not completely recovered from surgery
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,886 participants (actual)

Study arms

  • Active comparator
    5-Fluorouracil/Leucovorin (5-FU/LV)

    Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m\^2 IV bolus injection + 5-FU 425 mg/m\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m\^2 by two-hour IV infusion + 5-FU 500 mg/m\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).

    Drug: Leucovorin (LV) · Drug: 5-Fluorouracil (5-FU)

  • Experimental
    Capecitabine in Combination with Oxaliplatin (XELOX)

    Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).

    Drug: Capecitabine · Drug: Oxaliplatin

Interventions

  • 1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.

    Also known as: Xeloda

  • 130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.

  • Administered by one of two regimens, as specified in the arm description.

  • Administered by one of two regimens, as specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) [Number of Events]

    Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements.

    Time frame: Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).

  2. Disease-Free Survival (DFS) [Time to Event]

    Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.

    Time frame: Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).

Secondary outcomes

  1. Relapse-Free Survival (RFS) [Number of Events]

    A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment.

    Time frame: Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).

  2. Relapse-Free Survival (RFS) [Time to Event]

    A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.

    Time frame: Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).

  3. Overall Survival [Number of Events]

    Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.

    Time frame: Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).

  4. Overall Survival [Time to Event]

    Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.

    Time frame: Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).

  5. Number of Participants With at Least One Adverse Event by Most Severe Intensity

    The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details.

    Time frame: From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).

07

Results

Posted Jul 29, 2011

Participant flow

Participant flow — Overall Study
Milestone5-FU/LVXELOX
Started942944
Received treatment926938
Completed575619
Not completed367325
Withdrew: Death286242
Withdrew: Withdrawal by subject1820
Withdrew: Lost to follow-up6363

Outcome measures

PrimaryDisease-Free Survival (DFS) [Number of Events]

Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements.

Time frame:
Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).
Reported as:
Count of participants · Participants
Disease-Free Survival (DFS) [Number of Events]
Participants5-FU/LVXELOX
Patients with Event379320
Patients without Events563624
SecondaryRelapse-Free Survival (RFS) [Number of Events]

A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment.

Time frame:
Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).
Reported as:
Count of participants · Participants
Relapse-Free Survival (RFS) [Number of Events]
Participants5-FU/LVXELOX
Patients With Event356290
Patients Without Events586654
PrimaryDisease-Free Survival (DFS) [Time to Event]

Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.

Time frame:
Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months).
Reported as:
Median · months
Disease-Free Survival (DFS) [Time to Event]
months5-FU/LVXELOX
Disease-Free Survival (DFS) [Time to Event]NA (0 to 95)88.6 (0 to 89)
Statistical analysis
  • 5-FU/LV vs XELOX · Log Rank · p = 0.0038 (This test used a two-sided significance level of 5%.) · Hazard ratio (hr): 0.80 · 95% CI 0.69 to 0.93The hazard ratio was calculated as XELOX versus 5-FU/LV arms.
SecondaryRelapse-Free Survival (RFS) [Time to Event]

A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.

Time frame:
Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months).
Reported as:
Median · months
Relapse-Free Survival (RFS) [Time to Event]
months5-FU/LVXELOX
Relapse-Free Survival (RFS) [Time to Event]NA (0 to 95)88.6 (0 to 89)
Statistical analysis
  • 5-FU/LV vs XELOX · Log Rank · p = 0.0015 · Hazard ratio (hr): 0.78 · 95% CI 0.67 to 0.91The hazard ratio was calculated as XELOX versus 5-FU/LV arms.
SecondaryOverall Survival [Number of Events]

Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.

Time frame:
Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).
Reported as:
Count of participants · Participants
Overall Survival [Number of Events]
Participants5-FU/LVXELOX
Patients With Event286242
Patients Without Events656702
SecondaryOverall Survival [Time to Event]

Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.

Time frame:
Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).
Reported as:
Median · months
Overall Survival [Time to Event]
months5-FU/LVXELOX
Overall Survival [Time to Event]NA (0 to 95)NA (0 to 93)
Statistical analysis
  • 5-FU/LV vs XELOX · Log Rank · p = 0.0367 · Hazard ratio (hr): 0.83 · 95% CI 0.70 to 0.99The hazard ratio was calculated as XELOX versus 5-FU/LV arms.
SecondaryNumber of Participants With at Least One Adverse Event by Most Severe Intensity

The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details.

Time frame:
From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event by Most Severe Intensity
Participants5-FU/LV MAYO CLINIC5-FU/LV ROSWELL PARKXELOX
Mild AEs557256855
Moderate AEs493217792
Severe AEs299146548
Life-Threatening832163

Adverse events

Collected over From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5-FU/LV MAYO CLINIC215/664 (32.4%)134/657 (20.4%)622/657 (94.7%)
5-FU/LV ROSWELL PARK71/278 (25.5%)88/269 (32.7%)262/269 (97.4%)
XELOX242/944 (25.6%)208/938 (22.2%)926/938 (98.7%)
Most frequent serious events
Showing 10 of 184
Most frequent serious events
Event5-FU/LV MAYO CLINIC5-FU/LV ROSWELL PARKXELOX
DIARRHOEAGastrointestinal disorders39/65724/26955/938
FEBRILE NEUTROPENIABlood and lymphatic system disorders31/6572/2692/938
DEHYDRATIONMetabolism and nutrition disorders4/65710/26924/938
STOMATITIS ALLGastrointestinal disorders22/6570/2692/938
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders4/6575/2693/938
VOMITINGGastrointestinal disorders6/6573/26915/938
ILEUSGastrointestinal disorders2/6574/2693/938
ABDOMINAL PAINGastrointestinal disorders5/6573/26913/938
PYREXIAGeneral disorders2/6573/26912/938
NEUTROPENIABlood and lymphatic system disorders8/6572/2693/938
Most frequent other events
Showing 10 of 55
Most frequent other events
Event5-FU/LV MAYO CLINIC5-FU/LV ROSWELL PARKXELOX
DIARRHOEAGastrointestinal disorders449/657219/269577/938
NAUSEAGastrointestinal disorders350/657190/269625/938
STOMATITIS ALLGastrointestinal disorders419/65757/269195/938
FATIGUEGeneral disorders148/657170/269332/938
VOMITINGGastrointestinal disorders142/657103/269415/938
PARAESTHESIANervous system disorders16/65710/269339/938
NEUTROPENIABlood and lymphatic system disorders232/65736/269260/938
ABDOMINAL PAINGastrointestinal disorders118/65792/269204/938
NEUROPATHY PERIPHERALNervous system disorders8/65712/269279/938
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders56/65742/269278/938

Baseline characteristics

Age, Continuous
Age, Continuous(years)5-FU/LVXELOXTotal
Mean60.5 ± 10.7659.8 ± 10.9560.2 ± 10.86
Sex: Female, Male
Sex: Female, Male(Participants)5-FU/LVXELOXTotal
Female442431873
Male5005131013
Sex: Female, Male
Sex: Female, Male(Participants)5-FU/LVXELOXTotal
Female442431873
Male5005131013
08

Study locations

232 sites
  • The Cancer Center At Providence Park
    Mobile, Alabama 36608, United States
  • Central Hematology Oncology Medical Group Inc.
    Alhambra, California 91801, United States
  • Comprehensive Blood/Cancer Ctr
    Bakersfield, California 93309, United States
  • Virginia K. Crossen Cancer Center
    Fullerton, California 92835, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • West Valley Hematology Oncology The Thomas and Dorothy Leavey Cancer Center
    Northridge, California 91325, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • Wilshire Oncology Medical Group
    Pomona, California 91767, United States
  • Sutter Cancer Center
    Sacramento, California 95816, United States
  • Scripps Cancer Center
    San Diego, California 92121, United States
  • Kaiser Permanente San Diego; Hepatology Research
    San Diego, California 92154, United States
  • Santa Barbara Hematology Oncology Medical Group, Inc.
    Santa Barbara, California 93105, United States
  • San Diego Cancer Center'S Medical Group
    Vista, California 92083, United States
  • Innovative clinical research institute/American institute of research
    Whittier, California 90603, United States
  • University of Colorado Health Science Center; Biomedical Research Bldg. Room 511
    Aurora, Colorado 80045, United States
  • Hematology Oncology Associates
    Fort Collins, Colorado 80528, United States
  • Hematology Oncology P.C.
    Stamford, Connecticut 06902, United States
  • Georgetown Uni Medical Center; Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Lakeland Regional Cancer Center
    Lakeland, Florida 33804-1057, United States
  • Uni of Miami School of Medicine; Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Georgia Cancer Specialists
    Atlanta, Georgia 30341, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • Ochsner Cancer Inst.
    New Orleans, Louisiana 70121, United States
  • Park Nicollet Clinic Cancer Center
    Saint Louis Park, Minnesota 55416, United States
  • St Joseph Oncology
    Saint Joseph, Missouri 64507, United States
  • Hematology Oncology Consultants, Inc.
    Saint Louis, Missouri 63136, United States
  • Hematology-Oncology Centers of the Northern Rockies
    Billings, Montana 59101, United States
  • Great Falls Clinic
    Great Falls, Montana 59405, United States
  • Va Medical Center
    Reno, Nevada 89502, United States
  • Nh Oncology Hematology, Pa
    Hooksett, New Hampshire 03106, United States
  • Morristown Medical Center;Hematology-Oncology Assoc
    Morristown, New Jersey 07962, United States
  • Overlook Oncology Center; Summit Medical Group
    Summit, New Jersey 07901, United States
  • New Mexico Oncology Hematology Consultants
    Albuquerque, New Mexico 87109, United States
  • St. Vincent'S Hospital; Comprehensive Care Center
    New York, New York 10011, United States
  • Presbyterian Healthcare; Cancer Research Dept
    Charlotte, North Carolina 28233-3549, United States
  • Moses Cone Reg Cancer Ctr
    Greensboro, North Carolina 27403, United States
  • Carolina Oncology Specialists, PA - Hickory
    Hickory, North Carolina 28602, United States
  • Oncology-Hematology of Lehigh Valley, Pc
    Bethlehem, Pennsylvania 18015, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • Hospital of the Uni of Pennsylvania; Section of Hematology/Oncology
    Philadelphia, Pennsylvania 19104-4283, United States
  • Fox Chase-Temple Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Uni of Pittsburgh Cancer Inst. ; Oncology
    Pittsburgh, Pennsylvania 15232, United States
  • West Clinic
    Germantown, Tennessee 38138, United States
  • US Oncology
    The Woodlands, Texas 77380, United States
  • Intermountain Hematology & Oncology
    Salt Lake City, Utah 84106, United States
  • Internal Medicine Associates of Yakima Inc.
    Yakima, Washington 98902, United States
  • UNI OF WISCONSIN SCHOOL OF MEDICINE; GI Oncology Research Group, Paul P Carbone Cancer Center
    Madison, Wisconsin 53792, United States
  • Royal Prince Alfred Hospital; Medical Oncology
    Camperdown, New South Wales 2050, Australia
  • Port Macquarie Base Hospital; Oncology
    Port Macquarie, New South Wales 2444, Australia
  • Southern Medical Day Care; Clinical Trials Unit
    Wollongong, New South Wales 2500, Australia
  • Queen Elizabeth Hospital; Medical Oncology
    Woodville South, South Australia 5011, Australia
  • Box Hill Hospital; Oncology
    Box Hill, Victoria 3128, Australia
  • Footscray Hospital
    Footscray, Victoria 3011, Australia
  • St John of God Hospital; Medical Oncology
    Perth, Western Australia 6008, Australia
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • GHdC Site Notre Dame
    Charleroi, 6000, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Hospital de Baleia; Serviço de Oncologia Clínica
    Belo Horizonte, MG 30285-000, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-120, Brazil
  • Hospital das Clinicas - FMUSP; Gastroenterologia
    Sao Paulo, SP 05403-000, Brazil
  • Tom Baker Cancer Centre; Dept of Medicine
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute ; Dept of Medical Oncology
    Edmonton, Alberta T6G 1Z2, Canada
  • Bcca - Cancer Center Southern Interior
    Kelowna, British Columbia V1Y 5L3, Canada
  • Bcca-Fraser Valley Cancer Centre
    Surrey, British Columbia V3V 1Z2, Canada
  • Bcca - Vancouver Island Cancer Centre; Oncology
    Victoria, British Columbia V8R 6V5, Canada
  • St. Boniface General Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
  • Dr. H. Bliss Murphy Cancer Centre; Oncology
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Queen Elizabeth II Health Sciences Centre; Oncology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Hamilton Health Sciences - Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Regional Cancer Centre
    London, Ontario N6A 4L6, Canada
  • Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre
    Mississauga, Ontario L5M 2N1, Canada
  • Lakeridge Health Oshawa; Oncology
    Oshawa, Ontario L1G 2B9, Canada
  • The Ottawa Hospital Cancer Centre; Oncology
    Ottawa, Ontario K1H 8L6, Canada
  • Humber River Hospital
    Toronto, Ontario M3M 0B2, Canada
  • Sunnybrook Health Science Centre
    Toronto, Ontario M4N 3M5, Canada
  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept
    Toronto, Ontario M5G 2M9, Canada
  • Cite de La Sante de Laval; Hemato-Oncologie
    Laval, Quebec H7M 3L9, Canada
  • Hotel Dieu de Levis; Oncology
    Levis, Quebec G6V 3Z1, Canada
  • Hopital Maisonneuve- Rosemont; Oncology
    Montreal, Quebec H1T 2M4, Canada
  • Chum Campus Notre Dame
    Montreal, Quebec H2X 0A9, Canada
  • McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
    Montreal, Quebec H3T 1E2, Canada
  • Hopital Du Sacre Coeur de Montreal; Pneumologie
    Montreal, Quebec H4J 1C5, Canada
  • Chuq - Hopital Hotel Dieu de Quebec; Oncology
    Quebec City, Quebec G1R 2J6, Canada
  • Cancer Hospital Chinese Academy of Medical Sciences.
    Beijing, 100021, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, 510515, China
  • The Second Affiliated Hospital of Zhejiang University College
    Hangzhou, 310009, China
  • The 1st Affiliated Hospital of Nanchang Unversity
    Nanchang, 330006, China
  • Jiangsu Cancer Hospital
    Nanjing, 210009, China
  • Shandong Cancer Hospital; Oncology
    Shandong, 250117, China
  • Fudan University Shanghai Cancer Center
    Shanghai City, 200120, China
  • Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
    Shanghai, 200025, China
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, 200092, China
  • Tianjin Cancer Hospital
    Tianjin, 300060, China
  • Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
    Wuhan, 430030, China
  • Tampere University Hospital; Dept of Oncology
    Tampere, 33520, Finland
  • Turku Uni Central Hospital; Oncology Clinics
    Turku, 20520, Finland
  • Hopital Louis Pasteur; Medecine B
    Colmar, 68024, France

Showing the first 100 of 232 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, Andre T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023 Feb 1;41(4):803-815. doi: 10.1200/JCO.21.02726. Epub 2022 Oct 28. PubMed 36306483 ↗
  • Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107. Epub 2015 Aug 31. PubMed 26324362 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2003 to primary completion in Apr 2011, 96 months.

Results were first posted in Jul 2011, 3 months after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 96 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2003
First posted
Sep 18, 2003
StartActual
Apr 18, 2003
Primary completionActual
Apr 21, 2011
CompletionActual
Apr 21, 2011
Results first posted
Jul 29, 2011
Last update
Mar 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00069121
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 18, 2003
Start date
Apr 18, 2003
Primary completion
Apr 21, 2011
Completion
Apr 21, 2011
Results posted
Jul 29, 2011
Last update
Mar 6, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Oxaliplatin

Start the discussion